Sarah Noonberg

Dr. Noonberg has more than 15 years of industry experience leading development programs from discovery to commercialization across a range of indications. Most recently she was Chief Medical Officer at Nohla Therapeutics from May 2018 to May 2019, leading development of a universal cell therapy for hematologic malignancies. Prior to joining Nohla, she held multiple executive leadership roles including Global Head of Clinical Development at BioMarin where she advanced a broad portfolio of development programs including cerliponase alfa (Brineura™) for CLN2 disease, pegvaliase (Palynziq™) for phenylketonuria, and gene therapy for hemophilia A. Prior to BioMarin, she was Senior Vice President at Medivation where she was responsible for translational and early development activities as well as led late stage development of enzalutamide (XTANDI™) for advanced prostate cancer. Dr. Noonberg currently serves on the Board of Directors at Protagonist Therapeutics and is a member of the audit committee. She trained in internal medicine residency at Johns Hopkins, received an MD from the University of California, San Francisco, a PhD in bioengineering from the University of California, Berkeley, and a BS in engineering science from Dartmouth College.